公开(公告)号：US20050046332A1

公开(公告)日：2005-03-03

申请号：US10961140

申请日：2004-10-12

申请人： Hisao Tajima ,  Toshimitsu Kawase

发明人： Hisao Tajima ,  Toshimitsu Kawase

IPC分类号： H01J9/32 ,  H01J29/92 ,  H01J31/12 ,  H01J63/04 ,  H01J1/62

CPC分类号： H01J9/32 ,  H01J29/925 ,  H01J2329/00

摘要： Abnormal discharge of an electron-emitting apparatus is suppressed and-a thin electric earth connection structure is realized at a low cost. An image-forming apparatus has: a rear plate formed with electron-emitting devices; a face plate facing the rear plate, the face plate being formed with a phosphor which displays an image by emitting light upon incidence of an electron beam emitted from the electron-emitting device and an electrode applied with a voltage to accelerate the electron beam; a frame sandwiched and coupled between the rear and face plates and constituting a vacuum container together with the rear and face plates; a high voltage introducing member for introducing a high voltage from a voltage source; and an independent wire which is electrically independent from the high voltage introducing member and formed surrounding a high voltage area in the vacuum container, wherein a resistor film is formed between the high voltage introducing member and the independent wire. The wire is formed inside and outside of the vacuum container and is connected to an earth potential.

摘要翻译： 抑制了电子发射装置的异常放电，并且以低成本实现了薄的电接地结构。 图像形成装置具有：形成有电子发射装置的后板; 所述面板面对所述后板，所述面板形成有荧光体，所述荧光体通过在从所述电子发射器件发射的电子束入射时发射光而显示图像，以及施加电压以加速所述电子束的电极; 框架夹在并联接在后板和面板之间并与后板和面板一起构成真空容器; 用于从电压源引入高电压的高压引入部件; 以及与高压引入部件电气独立并且形成在真空容器内的高电压区域的独立电线，其中在高压引入部件和独立焊丝之间形成电阻膜。 导线形成在真空容器的内部和外部并连接到地电位。

公开(公告)号：US06831708B2

公开(公告)日：2004-12-14

申请号：US09902569

申请日：2001-07-12

申请人： Hisao Tajima

发明人： Hisao Tajima

IPC分类号： H07L2906

CPC分类号： H04N5/642

摘要： As a structure capable of housing a recording/reproducing unit within a thin type image display apparatus without damaging the characteristic of the thin-type image display apparatus such as a wall-hung TV when using the unit, there is provided an image display apparatus having a flat display panel and a casing that supports the display panel wherein a recording/reproducing unit that houses a storage medium therein and conducts the writing or reading with respect to the storage medium is supported substantially in parallel with the display panel within the casing. The image display apparatus is capable of changing the arrangement direction of the storage medium, suppressing an interference of the storage medium with a peripheral device at the time of projecting the storage medium, and housing the storage medium so as not to be superimposed on the display panel.

摘要翻译： 作为能够在薄型图像显示装置中容纳记录/再现单元而不损害诸如壁挂TV的薄型图像显示装置的特性的结构，作为一种结构，提供了一种图像显示装置， 支撑显示面板的平板显示面板和壳体，其中容纳其中的存储介质并且相对于存储介质进行写入或读取的记录/再现单元与壳体内的显示面板基本上平行地支撑。 图像显示装置能够改变存储介质的布置方向，在投影存储介质时抑制存储介质与外围设备的干扰，并且容纳存储介质以便不叠加在显示器上 面板。

公开(公告)号：US06821994B2

公开(公告)日：2004-11-23

申请号：US10428096

申请日：2003-05-02

申请人： Hisao Tajima ,  Yoshisuke Nakayama ,  Daikichi Fukushima

发明人： Hisao Tajima ,  Yoshisuke Nakayama ,  Daikichi Fukushima

IPC分类号： A61K314427

CPC分类号： C07D413/06 ,  C07D413/14 ,  C07D417/06

摘要： A peroxisome proliferator activated receptor regulator containing a compound of formula (I) (wherein all symbols are as defined in the specification), or a salt thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diabetes or syndrome X.

摘要翻译： 含有式（I）化合物（其中所有符号如说明书中所定义）或其盐作为活性成分的过氧化物酶体增殖物激活受体调节剂。由于具有调节PPAR的作用，式（I）化合物 可用作降血糖药物，降血脂药物，与代谢紊乱（糖尿病，肥胖症，综合征X，高胆固醇血症，高脂蛋白血症等）相关疾病，高脂血症，动脉粥样硬化，高血压，循环系统疾病，暴饮暴食的疾病的预防和/或补救措施， 冠心病等，HDL胆固醇升高剂，LDL胆固醇和/或VLDL胆固醇降低剂和用于缓解糖尿病或综合征X的危险因素的药物。

公开(公告)号：US06432913B1

公开(公告)日：2002-08-13

申请号：US09558340

申请日：2000-04-26

申请人： Hisao Tajima ,  Koichiro Kitagawa ,  Hiroyuki Ohno

发明人： Hisao Tajima ,  Koichiro Kitagawa ,  Hiroyuki Ohno

IPC分类号： A01N6100

CPC分类号： C07K14/47 ,  A61K38/00

摘要： The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the said polypeptide; vector derived the said DNA; host cells transformed the said vector; antibody of the said polypeptide; pharmaceutical composition containing the said peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the said protein p140; agent for the prevention and/or treatment for the currently said the prevention and/or treatment method; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylation of protein p140, as active ingredient and the screening methods of the said prevention and/or treatment agent. Tyrosine phosphorylation of protein p140 is an essential step in the induction of hypoglycemia by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention is not only improve the diabetes-derived hyperglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

摘要翻译： 本发明涉及胰岛素信号传递系统中涉及的关键蛋白质的新型蛋白质p140多肽， 制备方法 编码所述多肽的DNA; 载体衍生所述DNA; 宿主细胞转化所述载体; 所述多肽的抗体; 含有所述肽或抗体的药物组合物; 用于预防和/或治疗糖尿病的方法，其特征在于所述蛋白质p140的酪氨酸磷酸化; 用于预防和/或治疗目前所述的预防和/或治疗方法的药剂; 用于预防和/或治疗糖尿病的药物，其特征在于含有可以作为活性成分的蛋白质p140的酪氨酸磷酸化的化合物和所述预防和/或治疗剂的筛选方法。蛋白质p140的酪氨酸磷酸化是 通过葡萄糖摄取诱导低血糖的关键步骤。 本发明中基于蛋白质p140的酪氨酸磷酸化的预防和/或治疗方法和药剂不仅可以改善糖尿病来源的高血糖状况，而且可用于治疗和/或预防糖尿病，特别是非胰​​岛素依赖型糖尿病 （NIDDM）。

公开(公告)号：US06303320B1

公开(公告)日：2001-10-16

申请号：US09192435

申请日：1998-01-08

申请人： Hisao Tajima ,  Koichiro Kitagawa ,  Hiroyuki Ohno

发明人： Hisao Tajima ,  Koichiro Kitagawa ,  Hiroyuki Ohno

IPC分类号： G01N3353

CPC分类号： C07K14/47 ,  A61K38/00

摘要： The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the polypeptide; vector derived with the DNA; host cells transformed with the vector; antibody of the polypeptide; pharmaceutical composition containing the peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the protein p140; agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylate protein p140, as active ingredient and the screening methods of the prevention and/or treatment agent. Tyrosine phosphorylation of protein p140 is an essential step in the induction of hypoglycemia by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention not only improve the diabetes-derived hyperglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

摘要翻译： 本发明涉及胰岛素信号传递系统中涉及的关键蛋白质的新型蛋白质p140多肽， 制备方法 编码多肽的DNA; 用DNA衍生的载体; 宿主细胞用载体转化; 多肽的抗体; 含有肽或抗体的药物组合物; 用于预防和/或治疗糖尿病的方法，其特征在于蛋白质p140的酪氨酸磷酸化; 用于预防和/或治疗糖尿病的药物，其特征在于含有可以酪氨酸磷酸化蛋白质p140的化合物作为活性成分和预防和/或治疗剂的筛选方法。 蛋白质p140的酪氨酸磷酸化是通过葡萄糖摄取诱导低血糖的关键步骤。 本发明中基于蛋白质p140的酪氨酸磷酸化的预防和/或治疗方法和药剂不仅改善糖尿病衍生的高血糖病症，而且可用于治疗和/或预防糖尿病，特别是非胰​​岛素依赖性糖尿病 （NIDDM）。

公开(公告)号：US5804411A

公开(公告)日：1998-09-08

申请号：US571785

申请日：1995-12-13

申请人： Hisao Tajima ,  Koichiro Kitagawa ,  Hiroyuki Ohno

发明人： Hisao Tajima ,  Koichiro Kitagawa ,  Hiroyuki Ohno

IPC分类号： A61K38/00 ,  C07K14/47 ,  C12N1/21 ,  C12N15/12 ,  C12P21/08 ,  C12P21/02 ,  C07H21/04 ,  C12N15/63

CPC分类号： C07K14/47 ,  A61K38/00

摘要： The present invention is related to a novel protein p140 polypeptide which is a key protein involved in the signal transmission system of insulin; method for preparation of it; DNA encoding the said polypeptide; vector derived the said DNA; host cells transformed the said vector; antibody of the said polypeptide; pharmaceutical composition containing the said peptide or antibody; method for the prevention and/or treatment of diabetes, which is characterized by tyrosine phosphorylation of the said protein p140; agent for the prevention and/or treatment of diabetes, agent for the prevention and/or treatment of diabetes, which is characterized by containing a compound which can tyrosine phosphorylate of protein p140, as active ingredient and the screening methods of the said prevention and/or treatment agent. Tyrosine phosphorylation of protein p140 is an essential step in the induction of hypoglycemia by glucose uptake. Method and agent of prevention and/or treatment based on tyrosine phosphorylation of protein p140 in the present invention is not only to improve the diabetes-derived hypoglycemic conditions but are also useful for the treatment and/or prevention of diabetes, especially non-insulin dependent diabetes mellitus (NIDDM).

摘要翻译： 本发明涉及胰岛素信号传递系统中涉及的关键蛋白质的新型蛋白质p140多肽， 制备方法 编码所述多肽的DNA; 载体衍生所述DNA; 宿主细胞转化所述载体; 所述多肽的抗体; 含有所述肽或抗体的药物组合物; 用于预防和/或治疗糖尿病的方法，其特征在于所述蛋白质p140的酪氨酸磷酸化; 用于预防和/或治疗糖尿病的药剂，用于预防和/或治疗糖尿病的药剂，其特征在于含有可以将蛋白质p140的酪氨酸磷酸化的化合物作为活性成分，以及所述预防和/ 或治疗剂。 蛋白质p140的酪氨酸磷酸化是通过葡萄糖摄取诱导低血糖的关键步骤。 基于本发明的蛋白质p140的酪氨酸磷酸化的预防和/或治疗方法和药剂不仅可改善糖尿病衍生的低血糖状况，而且可用于治疗和/或预防糖尿病，特别是非胰​​岛素依赖性 糖尿病（NIDDM）。

公开(公告)号：US5587817A

公开(公告)日：1996-12-24

申请号：US228274

申请日：1994-04-15

申请人： Takao Miyamoto ,  Hisao Tajima

发明人： Takao Miyamoto ,  Hisao Tajima

IPC分类号： G02F1/13 ,  G02F1/1333 ,  G09F9/00

CPC分类号： G02F1/1333 ,  G02F2001/133354

摘要： A liquid crystal panel is fixed onto a fixing plate through a reduced number of operational steps by disposing in advance a plurality of height-regulating pins on the fixing plate so as to facilitate the control of a spacing between the liquid crystal panel and the fixing plate before the curing of an adhesive between the liquid crystal panel and the fixing plate. The height-regulating pins after the curing of the adhesive are removed, e.g., by thermal melt-cutting or ultrasonic cutting.

摘要翻译： 通过在固定板上预先设置多个高度调节销以便于控制液晶面板和固定板之间的间隔，通过减少操作步骤将液晶面板固定在固定板上 在液晶面板和固定板之间的粘合剂固化之前。 粘合剂固化后的高度调节销例如通过热熔切割或超声波切割被去除。

公开(公告)号：US07608411B2

公开(公告)日：2009-10-27

申请号：US11470213

申请日：2006-09-05

申请人： Hisao Tajima

发明人： Hisao Tajima

IPC分类号： G01N33/53

CPC分类号： G01N33/88 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/72 ,  C07K16/2869

摘要： (1) A novel polypeptide prostaglandin E receptor, (2) a cDNA encoding the polypeptide and a fragment selectively hybridized to the sequence of the cDNA, (3) a replication or expression vector carrying the DNA, (4) a host cell transformed with the replication or the expression vector, (5) a method for producing the polypeptide which comprises culturing the host cells, (6) a monoclonal or polyclonal antibody against the polypeptide, (7) a pharmaceutical composition containing the polypeptide or the antibody, in association with pharmaceutically acceptable excipient and/or antibody, (8) a screening method for a compound having agonistic or antagonistic activity against EP1, comprising using the polypeptide or the host cell.The polypeptide of the present invention can be used for treating diseases, which is caused by over production of PGE2, such as pain, fever and pollakiuria.

摘要翻译： （1）一种新的多肽前列腺素E受体，（2）编码多肽的cDNA和与cDNA序列有选择性杂交的片段，（3）载有DNA的复制或表达载体，（4） 复制或表达载体，（5）生产多肽的方法，其包括培养宿主细胞，（6）针对多肽的单克隆抗体或多克隆抗体，（7）包含多肽或抗体的药物组合物 与药学上可接受的赋形剂和/或抗体，（8）对EP1具有激动作用或拮抗活性的化合物的筛选方法，包括使用多肽或宿主细胞。 本发明的多肽可用于治疗由过度产生PGE2引起的疾病，例如疼痛，发热和尿频。

公开(公告)号：US20070167490A1

公开(公告)日：2007-07-19

申请号：US10548650

申请日：2004-03-12

申请人： Akiharu Ishida ,  Shinya Kusuda ,  Yoshisuke Nakayama ,  Hisao Tajima ,  Tomoyuki Kido ,  Tetsuya Kitamine

发明人： Akiharu Ishida ,  Shinya Kusuda ,  Yoshisuke Nakayama ,  Hisao Tajima ,  Tomoyuki Kido ,  Tetsuya Kitamine

IPC分类号： A61K31/4439 ,  A61K31/44 ,  A61K31/381 ,  A61K31/415

CPC分类号： C07D213/30 ,  C07C251/54 ,  C07D207/20 ,  C07D209/08 ,  C07D211/70 ,  C07D213/50 ,  C07D213/53 ,  C07D213/55 ,  C07D231/12 ,  C07D233/54 ,  C07D249/08 ,  C07D257/04 ,  C07D277/04 ,  C07D295/13 ,  C07D307/52 ,  C07D319/08 ,  C07D333/22 ,  C07D403/12 ,  C07D407/10 ,  C07D407/12 ,  C07D409/04 ,  C07D417/10

摘要： The compound represented by formula (I) (wherein R1 and R2 are cyclic group which may have a substituent(s) and so on; W is a spacer of which main chain has an atom number of 1-6.; X is —O— and so on; ring A is cyclic group which may have a substituent(s); Y is a spacer of which main chain has an atom number of 1-6 and so on; Z is acidic group.) a salt thereof, a solvent thereof or an N-oxide thereof, or a prodrug thereof Since the compounds in the present invention have a regulatory activity for peroxisome proliferator activated receptor, the compounds in the present invention are useful as a preventive and/or therapeutic agent for diseases associating metabolic disorders (e.g., hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipidemia, atherosclerosis, hypertension, circulatory diseases, overeating, ischemic heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or a VLDL cholesterol-lowering agent and a drug for relief from risk factors of diabetes or metabolic syndrom.

摘要翻译： 由式（I）表示的化合物（其中R 1和R 2）是可以具有取代基等的环状基团; W是其中的间隔基 主链的原子数为1-6; X为-O-等;环A为可具有取代基的环状基团; Y为主链的原子数为1〜 6等等; Z是酸性基团）其盐，其溶剂或其N-氧化物或其前药由于本发明的化合物对过氧化物酶体增殖物激活受体具有调节活性，所以化合物 本发明可用作将代谢紊乱（例如高胆固醇血症，高脂蛋白血症等），高脂血症，动脉粥样硬化，高血压，循环系统疾病，暴饮暴食，缺血性心脏病等相关的疾病的预防和/或治疗剂，HDL胆固醇 - 升高剂，LDL胆固醇和/或VLDL胆固醇降低剂和用于缓解ris的药物 k因素糖尿病或代谢综合征。

公开(公告)号：US07220864B2

公开(公告)日：2007-05-22

申请号：US10451679

申请日：2001-12-21

申请人： Hisao Tajima ,  Yoshisuke Nakayama ,  Daikichi Fukushima

发明人： Hisao Tajima ,  Yoshisuke Nakayama ,  Daikichi Fukushima

IPC分类号： C07D263/32

CPC分类号： C07D407/04 ,  C07D263/32 ,  C07D277/40 ,  C07D277/42 ,  C07D413/04 ,  C07D413/12 ,  C07D417/04

摘要： The compound 3-(5-(2-(2-(4-methylphenyl)-5-methyloxazol-4-yl)ethoxy)-3,4-dihydronaphthalene-1-yl)propanoic acid or a nontoxic salt thereof. Because this compound has activity of regulating peroxisome proliferators activated receptor regulator, it is useful as a hyperglycemic agent, a hypolipidemic agent, a preventative and/or treatment agent for diseases associated with metabolic disorders etc.

摘要翻译： 化合物3-（5-（2-（2-（4-甲基苯基）-5-甲基恶唑-4-基）乙氧基）-3,4-二氢萘-1-基）丙酸或其无毒盐。 因为这种化合物具有调节过氧化物酶体增殖物激活受体调节剂的活性，所以它可用作高血糖剂，降血脂剂，与代谢紊乱相关疾病的预防和/或治疗剂。